Key Developments For ThermoGenesis Corp.
ThermoGenesis Corp. (KOOL.O) (Consolidated Issue listed on NASDAQ Capital Market)
ThermoGenesis Corp. Comments On Q3, Q4 2010 Earnings Guidance-Conference Call
ThermoGenesis Corp. announced that it expects to reach breakeven in the third quarter of 2010 and profitability in the fourth quarter of 2010.
ThermoGenesis Corp. Announces Expanded Collaboration With SpineSmith, LLC's Celling Technologies
ThermoGenesis Corp. announced an expanded collaboration with Celling Technologies (Celling), a subsidiary of SpineSmith, LLC, related to the Company's bone marrow products, MXP MarrowXpress (MXP) and Res-Q 60 BMC (Res-Q). As part of this expanded collaboration, ThermoGenesis and Celling will share in the funding for clinical studies to demonstrate the clinical effectiveness of both the MXP and Res-Q Systems with Celling's orthopedic applications. Incremental funding for clinical studies will be provided by ThermoGenesis and Celling as MXP and Res-Q sales grow. Celling will be responsible for coordinating the clinical trials.
ThermoGenesis Corp. Updates FY 2009 Revenue Outlook To A Range Below Analysts' Estimates; Issues Q4 2009 Earnings Outlook Below Analysts' Estimates
ThermoGenesis Corp. updated its fiscal 2009 outlook and expects revenues to be in the range of $19.5-$20.0 million. For fourth quarter of 2009, it expects to report a loss in the range of $2.8-$3.3 million. According to Reuters Estimates, analysts were expecting the Company to report revenues of $22.1 million and net loss of $0.71 million for fourth quarter of 2009.
ThermoGenesis Corp. Updates FY 2009 Revenue Outlook Below Analysts' Estimates; Reaffirms FY 2010 Profit Outlook
ThermoGenesis Corp. announced that for fiscal 2009, it expects revenues to be essentially flat with fiscal 2008. For fiscal 2010, consistent with prior guidance, the Company anticipates reaching profitability. The Company reported revenue of $21.95 million in fiscal 2008. According to Reuters Estimates, analysts were expecting the Company to report revenue of $26 million for fiscal 2009; net profit of $2.90 million for fiscal 2010.
ThermoGenesis Corp. Appoints Chief Executive Officer
ThermoGenesis Corp. announced that it has named J. Melville Engle as Chief Executive Officer (CEO). Engle, is joining the Company effective April 14, 2009. Matthew Plavan, who has been serving as the Company's interim, has been named the Company's Chief Operating Officer.
